Feasibility of Home-Based Exercise in Primary Biliary Cholangitis: A Prospective Five-Patient Pilot Study with Body Composition, Quality-of-Life and Gut Microbiota Assessments

Abstract Background Evidence on exercise therapy in primary biliary cholangitis (PBC) remains limited, particularly regarding feasibility, body composition, quality of life, and the gut-liver axis. This prospective pilot study evaluated a 12-week home-based exercise program in outpatients with PBC. Methods The target sample size was five enrolled participants, chosen pragmatically to test recruitment, intervention delivery, adherence monitoring, serial clinical assessments and stool sampling rather than to test efficacy. Five female outpatients with PBC, including three with PBC alone and two with PBC/autoimmune hepatitis overlap, completed a home-based program combining walking and lower-limb resistance exercise. Primary feasibility outcomes were recruitment yield, completion of the intervention, attendance at the scheduled 3-month assessment, adherence to walking and resistance exercise, and exercise-related adverse events. Progression benchmarks for a future controlled study included recruitment of the planned sample, at least 80% completion, at least 80% follow-up attendance, acceptable safety, and interpretable adherence data. Results The recruitment target was reached: five of 35 assessed patients were enrolled (14.3%; exact 95% confidence interval [CI] 4.8–30.3%). All five participants completed the intervention and the 3-month assessment (100%; 95% CI 47.8–100%). No exercise-related adverse events occurred (0%; 95% CI 0-52.2%). Mean achievement of individualized step targets was 45%, below the desired adherence benchmark, whereas mean resistance-exercise adherence was 74%. Body weight was generally maintained, skeletal muscle index increased slightly in three patients, and 6-minute walk distance increased in four patients. Total bilirubin decreased descriptively over repeated measurements. Microbiota analyses showed no consistent pre-post separation in alpha diversity, beta diversity, genus-level composition or PICRUSt2-predicted pathways. Some descriptive genus-level shifts involved taxa that include butyrate-producing members, but fecal short-chain fatty acids were not measured. Conclusions The planned pilot sample was recruited, and progression benchmarks were met for intervention completion, follow-up attendance and safety in this 5-patient PBC pilot study. Walking adherence was below the desired benchmark and should be addressed before a larger controlled study. Clinical and microbiota results should be regarded as exploratory and hypothesis-generating. Trial registration UMIN Clinical Trials Registry, UMIN000051577. Registered 1 August 2023.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-10084232/v1
Primary Topic
Liver Diseases and Immunity
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Feasibility of Home-Based Exercise in Primary Biliary Cholangitis: A Prospective Five-Patient Pilot Study with Body Composition, Quality-of-Life and Gut Microbiota Assessments

Terai Shuji, Michiyuki Kawakami, Hiroyuki Abé, Naruhiro Kimura et al.
Research Square
Liver Diseases and Immunity
preprint

Feasibility of Home-Based Exercise in Primary Biliary Cholangitis: A Prospective Five-Patient Pilot Study with Body Composition, Quality-of-Life and Gut Microbiota Assessments

Terai Shuji, Michiyuki Kawakami, Hiroyuki Abé, Naruhiro Kimura, Yuichiro Hosoi, Suguru Miida, Motomichi Takahashi, Kentaro Tominaga, Tadashi Ariyoshi, Tomoaki Yoshida, Shunta Yakubo, Hiroteru Kamimura, Kenya Kamimura, Saori Endo, Kentaro Oka, Hiroki Maruyama, Tetsuya Tsuji, Masaru Kumagai, HIROKI NATSUI
preprint en

Abstract

Abstract Background Evidence on exercise therapy in primary biliary cholangitis (PBC) remains limited, particularly regarding feasibility, body composition, quality of life, and the gut-liver axis. This prospective pilot study evaluated a 12-week home-based exercise program in outpatients with PBC. Methods The target sample size was five enrolled participants, chosen pragmatically to test recruitment, intervention delivery, adherence monitoring, serial clinical assessments and stool sampling rather than to test efficacy. Five female outpatients with PBC, including three with PBC alone and two with PBC/autoimmune hepatitis overlap, completed a home-based program combining walking and lower-limb resistance exercise. Primary feasibility outcomes were recruitment yield, completion of the intervention, attendance at the scheduled 3-month assessment, adherence to walking and resistance exercise, and exercise-related adverse events. Progression benchmarks for a future controlled study included recruitment of the planned sample, at least 80% completion, at least 80% follow-up attendance, acceptable safety, and interpretable adherence data. Results The recruitment target was reached: five of 35 assessed patients were enrolled (14.3%; exact 95% confidence interval [CI] 4.8–30.3%). All five participants completed the intervention and the 3-month assessment (100%; 95% CI 47.8–100%). No exercise-related adverse events occurred (0%; 95% CI 0-52.2%). Mean achievement of individualized step targets was 45%, below the desired adherence benchmark, whereas mean resistance-exercise adherence was 74%. Body weight was generally maintained, skeletal muscle index increased slightly in three patients, and 6-minute walk distance increased in four patients. Total bilirubin decreased descriptively over repeated measurements. Microbiota analyses showed no consistent pre-post separation in alpha diversity, beta diversity, genus-level composition or PICRUSt2-predicted pathways. Some descriptive genus-level shifts involved taxa that include butyrate-producing members, but fecal short-chain fatty acids were not measured. Conclusions The planned pilot sample was recruited, and progression benchmarks were met for intervention completion, follow-up attendance and safety in this 5-patient PBC pilot study. Walking adherence was below the desired benchmark and should be addressed before a larger controlled study. Clinical and microbiota results should be regarded as exploratory and hypothesis-generating. Trial registration UMIN Clinical Trials Registry, UMIN000051577. Registered 1 August 2023.

Research Square
Keio University (JP), Miyarisan Pharmaceutical Co., Ltd. (Japan) (JP), Niigata University (JP)
Japan Agency for Medical Research and Development
Good health and well-being
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon